1. FRI0182 A Single Dose Study Comparing Pharmacokinetics, Safety, and Immunogenicity of M923 (A Proposed Biosimilar To Adalimumab), US-Sourced Adalimumab, and EU-Sourced Adalimumab in Healthy Subjects. (15th July 2016) Authors: Hillson, J.; Mant, T.; Ganguly, T.; Rosano, M.; Huntenburg, C.; Alai-Safar, M.; Darne, S.; Palmer, D.; Pavlova, B.; Doralt, J.; Reeve, R.; Goel, N.; Weilert, D.; Rhyne, P.; Caminis, J.; Roach, J. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 495 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. FRI0312 Abatacept exposure-response analysis and its impact on dose selection in lupus nephritis. (23rd January 2014) Authors: Suryawanshi, S.; Tagen, M.; Murthy, B.; Hillson, J.; Roy, A. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A480 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Pegylated interferons Lambda‐1a and alfa‐2a display different gene induction and cytokine and chemokine release profiles in whole blood, human hepatocytes and peripheral blood mononuclear cells. Issue 6 (June 2014) Authors: Freeman, J.; Baglino, S.; Friborg, J.; Kraft, Z.; Gray, T.; Hill, M.; McPhee, F.; Hillson, J.; Lopez‐Talavera, J. C.; Wind‐Rotolo, M. Journal: Journal of viral hepatitis Issue: Volume 21:Issue 6(2014) Page Start: e1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. SAT0185 Efficacy and safety of abatacept in lupus nephritis. (23rd January 2014) Authors: Furie, R.; Nicholls, K.; Cheng, T.T.; Houssiau, F.; Burgos-Vargas, R.; Chen, S.L.; Hillson, J.; Meadows-Shropshire, S.; Kinaszczuk, M.; Merrill, J.T. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 534 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. SAT0189 Comparative analysis of alternative outcome measures for use in lupus nephritis trials. (23rd January 2014) Authors: Wofsy, D.; Meadows–Shropshire, S.; Hillson, J.; Diamond, B. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 535 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. SAT0196 A DOUBLE BLIND, PLACEBO CONTROLLED, SINGLE ASCENDING DOSE (SAD) AND MULTIPLE ASCENDING DOSE (MAD) STUDY OF ALPN-101, A FIRST-IN-CLASS DUAL ICOS/CD28 ANTAGONIST, IN HEALTHY VOLUNTEERS (HV). (2nd June 2020) Authors: Yang, J.; Hillson, J.; Lickliter, J.; Manjarrez, K.; Tercero, A.; Wiley, J.; Means, G.; Sanderson, R.; Carley, K.; Peng, S. L. Journal: Annals of the rheumatic diseases Issue: Volume 79(2020)Supplement 1 Page Start: 1040 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. THU0222 B CELL MODULATORY VARIANT TNF RECEPTOR DOMAINS (VTDS) IDENTIFIED BY DIRECTED EVOLUTION TO INHIBIT BAFF AND APRIL, ALONE OR COMBINED WITH VARIANT IG DOMAINS (VIGD™) THAT INHIBIT T CELL COSTIMULATION, FOR THE TREATMENT OF SEVERE AUTOIMMUNE AND/OR INFLAMMATORY DISEASE. (2nd June 2020) Authors: Dillon, S. R.; Evans, L. S.; Rixon, M. W.; Kuijper, J.; Demonte, D.; Lewis, K. E.; Levin, S.; Kleist, K.; Mudri, S.; Bort, S.; Bhandari, J.; Ahmed-Qadri, F.; Yang, J.; Seaberg, M. A.; Wang, R.; Sanderson, R.; Wolfson, M. F.; Hillson, J.; Peng, S. L.; Swiderek, K. M. Journal: Annals of the rheumatic diseases Issue: Volume 79(2020)Supplement 1 Page Start: 338 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗